Investor Presentaiton
R&D investor presentation
40
Phase 1 results for AM833 and semaglutide showed a 17% weight
reduction after only 20 weeks
% change in
body weight
Weight loss for different doses of AM833 and
semaglutide in phase 1¹
Highlights from phase 1
0
-2
-4
-6
-8
-10
-12
-14
-16
-18
-20
0
4
8
12
Weeks
AM833 0.16 mg
sema 2.4 mg
AM833 0.3 mg
sema 2.4 mg
AM833 0.6 mg
sema 2.4 mg
sema 2.4 mg
Mean baseline: 95.1 kg
16
AM833 1.2 mg
sema 2.4 mg
20
- 9.5%
+
17.1%
•
•
AM833 2.4 mg
sema 2.4 mg
1 Data are observed means, 20 weeks phase 1b trial dosing increments with semaglutide (sema) and AM833 once-weekly
with a 16 week dose-escalation regimen. Data is based on the trial product estimand: treatment effect if all people adhered
to treatment and did not initiate other anti-obesity therapies
•
•
66% of people on AM833 + semaglutide
2.4 mg high dose achieved >15%
weight loss in 20 weeks
AM833-semaglutide 2.4 mg appeared safe
and well-tolerated
The level of GI disorders observed was
comparable to what was generally seen
for GLP-1s in monotherapy
Next steps
Multi-dose PK study of AM833-
semaglutide 2.4 mg expected to be
initiated in H2 2020
Phase 3 programme expected to begin in
2021
novo nordiskView entire presentation